Loading...
XSHG
600572
Market cap1.69bUSD
Dec 05, Last price  
4.72CNY
1D
-0.21%
1Q
5.36%
Jan 2017
-35.43%
IPO
315.36%
Name

Zhejiang CONBA Pharmaceutical Co.

Chart & Performance

D1W1MN
XSHG:600572 chart
P/E
19.15
P/S
1.83
EPS
0.25
Div Yield, %
4.24%
Shrs. gr., 5y
-1.30%
Rev. gr., 5y
-0.76%
Revenues
6.52b
-3.23%
866,407,567829,918,7491,237,594,2591,094,915,7491,406,541,5781,799,426,0842,122,816,2732,733,691,1962,924,158,4593,581,615,5465,301,970,1426,020,371,0545,293,966,7786,786,645,2926,768,292,9205,909,017,0206,150,860,5836,000,443,3936,732,797,0376,515,163,435
Net income
622m
+5.21%
43,627,54656,758,649106,131,69791,973,561101,216,594185,527,183280,227,613295,713,135417,369,662552,347,425440,371,501441,069,516711,116,240803,794,5060453,301,7392,017,463,206358,119,418591,572,941622,417,029
CFO
1.01b
+12.67%
117,647,28171,201,52579,984,20398,555,327153,393,899125,929,206188,357,115245,758,214235,355,284617,434,215831,260,038969,706,133712,266,959545,776,464925,500,5391,249,699,895889,935,2381,155,481,693898,640,7241,012,529,326
Dividend
May 31, 20240.2 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Zhejiang CONBA Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of traditional Chinese medicines and botanical products in China. It offers chemical medicines, Chinese patent medicines, eye health products, nutritional supplements, health supplies, healthy daily necessities and food products, and other personal care products. The company was formerly known as Lanxi Yunshan Pharmaceutical Factory and changed its name to Zhejiang CONBA Pharmaceutical Co.,Ltd. in October 1999. Zhejiang CONBA Pharmaceutical Co.,Ltd. was founded in 1969 and is headquartered in Hangzhou, China. Zhejiang CONBA Pharmaceutical Co.,Ltd. is a subsidiary of Zhejiang Traditional Chinese Medicine Health Industry Group Co., Ltd.
URL
http://www.conbapharm.com/
IPO date
Apr 12, 2004
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT